Image Sourced ShutterStock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ShareRoot has announced a two-for-three entitlement offer to raise roughly $950,000 to support a restructuring of the business into the digital healthcare industry
  • Almost one billion new shares will be issued at 0.1 cents per share and company directors have committed to taking part in the offer
  • This is the second re-branding of the company since it was founded in 2013
  • ShareRoot has cut costs by 40 per cent this year and has forecasted revenue for this financial year to reach a 90 per cent increase from last year
  • Company shares currently trade for 0.1 cents in a market cap of $1.57 million

ShareRoot is set to raise roughly $950,000 to support a restructuring of its business into a digital healthcare industry.

The company expects the two-for-three non-renounceable entitlement offer to provide enough money to drive a profitable business in the near term. Under the terms of the offer, almost one billion new shares will be issued at 0.1 cents per share, and company directors have committed to taking part in the offer.

Founded in 2013, the company initially focused on helping brands advertise on Pinterest. Since then, the company’s focus has changed. In 2014, ShareRoot rebranded itself as a legal-rights management and marketing platform.

Providing marketing data and a privacy protection ecosystem, ShareRoots served major clients like Johnson&Johnson, McDonald’s and Costco.

Now, the company has announced it is one again restructuring and has a “clear path forward” to success in the digital healthcare industry.

ShareRoot has seen no change to its share price of only 0.1 cents this year, but management spoke confidently to investors in an ASX release today and said it has already kicked several crucial goals for 2019.

Among these is a new leadership team with experience in health, marketing and technology, a financial restructuring and subsequent costs reduction, and a new technology pipeline designed to service biopharma, health and medtech markets.

The company says it has shut down most of its US operations and reduced staff numbers to effectively cut costs by 40 per cent. On top of this, ShareRoot management has forecast revenue for this financial year to reach a 90 per cent increase from last year.

ShareRoot CEO Michelle Gallaher said the company has found itself in an uphill battle, and its challenges over the past five months have sparked ShareRoots’ transformation.

“The company now has a technology pipeline loaded with four competitive opportunities to capture a leading edge in the global digital healthcare sector,” Michelle said.

“What we are developing is a unique convergence of artificial intelligence, real world healthcare data and social media, one of the most exciting new frontiers in the escalating digital transformation taking place in health,” she said.

ShareRoot shares remain unchanged today and continue to trade for 0.1 cents in a market cap of $1.57 million.

SRO by the numbers
More From The Market Online

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327,…

What it takes to get a new drug to market in Australia

In this latest version of Thematica from TMO, we're taking a break from mines and battery…

4DMedical partners with West Los Angeles VA Medical Center for Veteran lung imaging study

Respiratory imaging technology company, 4DMedical (ASX:4DX) has entered into a research agreement with the West Los…

Recce Pharma picks up Chinese patent for anti-infective drugs

Recce Pharmaceuticals (ASX:RCE) has confirmed its receipt of a patent in China to protect its class…